Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepatocellular carcinoma via targeting the PRMT1-SREBF1 axis-mediated lipid metabolism. The gene discussed is SREBF1; the disease is hepatocellular carcinoma.